复发成人恶性胶质瘤中替莫唑胺3天用药/11天停药给药方案安全性和可行性的回顾性分析
Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas.
作者信息
van Vugt Vincent A, Piccioni David E, Brown Bradley D, Brown Tiffany, Saria Marlon G, Juarez Tiffany, Kesari Santosh
机构信息
Center for Translational Neuro-Oncology, Department of Neurosciences, Moores Cancer Center, UC San Diego, La Jolla, CA, USA.
出版信息
CNS Oncol. 2014 Jul;3(4):257-65. doi: 10.2217/cns.14.29.
AIMS
We report the safety and feasibility of a 3 days on/11 days off temozolomide regimen for the treatment of recurrent malignant gliomas.
PATIENTS & METHODS: Fifteen adult patients were treated; 14 were treated with 300 mg/m(2) and one treated with 250 mg/m(2).
RESULTS
We reviewed the toxicity, progression-free survival (PFS), overall survival and objective response rate. Two patients (13%) experienced grade 3 nausea/vomiting and six patients (40%) experienced grade 3 lymphopenia. Dose reduction and treatment delay occurred in eight (53%) cases. One patient discontinued treatment due to uncontrolled nausea/vomiting. Median PFS for glioblastoma patients was 4.1 months and 6-month PFS was 25%. Twelve patients exhibited stable disease (86%), one patient (7%) had progressive disease and one patient (7%) showed a partial response.
CONCLUSION
The '3 on/11 off' temozolomide regimen for recurrent high-grade gliomas was tolerable and warrants further study in a larger, prospective study.
目的
我们报告一种为期3天治疗/11天休息的替莫唑胺方案治疗复发性恶性胶质瘤的安全性和可行性。
患者与方法
对15例成年患者进行了治疗；14例接受300mg/m²治疗，1例接受250mg/m²治疗。
结果
我们评估了毒性、无进展生存期（PFS）、总生存期和客观缓解率。2例患者（13%）出现3级恶心/呕吐，6例患者（40%）出现3级淋巴细胞减少。8例（53%）患者出现剂量减少和治疗延迟。1例患者因无法控制的恶心/呕吐而停止治疗。胶质母细胞瘤患者的中位PFS为4.1个月，6个月PFS率为25%。12例患者病情稳定（86%），1例患者（7%）病情进展，1例患者（7%）出现部分缓解。
结论
用于复发性高级别胶质瘤的“3天治疗/11天休息”替莫唑胺方案耐受性良好，值得在更大规模的前瞻性研究中进一步探索。
Zotero 插件